Centro Inmunologia Molecular (CIM)   Report issue

Government Phase 2
Founded: Havana Cuba (1994)

Organization Overview

First Clinical Trial
2015
NCT04110678
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Center of Molecular Immunology, Cuba | Centro Immunologia Molecular CIM Havana Cuba | Centro Inmunologia Molecular CIM Havana Cuba

Active Ingredients

Drugs in Phase 2 Trials (1)

epoetin (Epogen) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Parkinson Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1